Document Detail

Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.
MedLine Citation:
PMID:  23044602     Owner:  NLM     Status:  Publisher    
The clinical impact of pharmacogenomics remains a hot topic of current research efforts. Although pharmacogenomics of phase I metabolizing enzymes seems to have been well studied, knowledge on the clinical impact of genetic variability of phase II metabolizing enzymes and drug transporters is more limited. This paper reviews data on the pharmacogenomics of phase II metabolizing enzymes as well as of ATP binding cassette transporters and of solute carrier transporters focusing on clinical implications for drug efficacy and drug toxicity. The clinical impact of some of these polymorphisms has been well defined i.e. the association between polymorphisms of organic anion transporter polypeptides and statin induced myopathy. However, as the same drug may be substrate for different enzymes and different transporters, it is difficult to elucidate the impact of each polymorphism. Investigating the impact of multiple polymorphisms might be more clinically meaningful, although methodologically challenging.The Pharmacogenomics Journal advance online publication, 9 October 2012; doi:10.1038/tpj.2012.42.
E Ch Yiannakopoulou
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-09
Journal Detail:
Title:  The pharmacogenomics journal     Volume:  -     ISSN:  1473-1150     ISO Abbreviation:  Pharmacogenomics J.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101083949     Medline TA:  Pharmacogenomics J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Basic Medical Lessons Faculty of Health and Caring Professions Technological Educational Institute of Athens, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.
Next Document:  Pharmacogenetics of nonsteroidal anti-inflammatory drugs.